Page 1 | Search Results | Blood | American Society of Hematology

1-9 of 9

Sort by

Sort Order Select

Journal Articles

Progression of Follicular Lymphoma within 24 Months of First Treatment (POD -24) As a Predictor of Overall Survival - a Single Center Retrospective Analysis

Guy Bitansky, Elena Vasilev, MD, Maya Zlotnick, MD, Elena Ribakovsky, MD, Ohad Benjamini, MD, Arnon Nagler, MD MSc, Abraham Avigdor, MD, Meirav Kedmi, MD

Blood (2019) 134 (Supplement_1): 1534.

https://doi.org/10.1182/blood-2019-125218

Published: 2019

Journal Articles

Ibrutinib, Bendamustine, Rituximab Combination for Relapsed and Refractory Aggressive B Cell Lymphoma — Interim Analysis of Phase II Clinical Trial

Meirav Kedmi, MD, Elena Ribakovsy, MD, Ohad Benjamini, MD, Ginette Schiby, MD, Iris Barshack, MD, Stephen P Raskin, MD, Yael Eshet, MD, Ramit Mehr, PhD, Guy Bitansky, Arnon Nagler, MD, Abraham Avigdor, MD

Blood (2018) 132 (Supplement 1): 4186.

https://doi.org/10.1182/blood-2018-99-111658

Published: 2018

Journal Articles

Evaluation of the Risk of Hepatitis B Reactivation Among Patients with Chronic Myeloid Leukemia Treated with Tyrosine Kinase Inhibitors

Ohad Benjamini, MD, Maya Zlotnick, MD, Elena Ribakovsky, MD, Meirav Kedmi, MD, Adrian Duek, MD, Drorit Merkel, MD, Merav Leiba, MD, Ivetta Danylesko, MD, Noga Shem-Tov, MD, Ronit Yerushalmi, MD, Avichai Shimoni, MD, Abraham Avigdor, MD, Arnon Nagler, Yulia Volchek, MD

Blood (2016) 128 (22): 5429.

https://doi.org/10.1182/blood.V128.22.5429.5429

Published: 2016

Journal Articles

Prognostic Value of Interim and End of Treatment FDG-PET/CT Scan Results in Adult Patients with Burkitt Lymphoma - a Retrospective Analysis of a Single Center Cohort

Eldar Priel, MD, Meirav Kedmi, MD, Tima Davidson, MD, Ginette Schiby, MD, Elena Ribakovsky, MD, Ohad Benjamini, MD, Arnon Nagler, MD MSc, Abraham Avigdor, MD

Blood (2015) 126 (23): 5025.

https://doi.org/10.1182/blood.V126.23.5025.5025

Published: 2015

Journal Articles

High Risk Advanced Stage Hodgkin Lymphoma Is Well Controlled with 2 Cycles of Escalated Beacopp Followed By 4 Cycles of ABVD in Patients Who Rapidly Achieve Metabolic CR on Interim PET/CT Scan

Meirav Kedmi, MD, Arie Apel, MD, Tima Davidson, MD, Elinor Goshen, MD, Yaron Davidovitz, MD, Miriam Berkowicz, MD, Itai Levi, MD, Eldad J. Dann, MD, Aaron Polliack, MD, Arnon Nagler, MD, Abraham Avigdor, MD

Blood (2014) 124 (21): 4442.

https://doi.org/10.1182/blood.V124.21.4442.4442

Published: 2014

Journal Articles

Low Proliferation Index May Be Associated with Longer Time to First Therapy In Low Grade Follicular Lymphoma

Meirav Kedmi, MD, Cyrus V. Hedvat, MD, PhD, Jocelyn Maragulia, Andrew D Zelenetz, MD

Blood (2010) 116 (21): 4149.

https://doi.org/10.1182/blood.V116.21.4149.4149

Published: 2010

Journal Articles

Drug Metabolism and Disposition Genes in Israeli HIV Patients: MDR1 and CYP3A4 Polymorphisms May Affect Susceptibility to HIV but Not the Course of the Disease.

Meirav Kedmi, MD, Sara Bar Cohen, PhD, Michelle Hauzi, RN, Shlomo Maayan, MD, Deborah Rund, MD

Blood (2005) 106 (11): 1434.

https://doi.org/10.1182/blood.V106.11.1434.1434

Published: 2005

Journal Articles

MDR1 Polymorphisms but Not GST Null Phenotypes Alter Susceptibility to Acute Myeloid Leukemia in Young Adult Israeli Patients.

Nava Asher, BSc Med, Sara Bar Cohen, PhD, Meirav Kedmi, MD, Maya Heled, Angela Risch, PhD, Deborah Rund, MD

Blood (2005) 106 (11): 2756.

https://doi.org/10.1182/blood.V106.11.2756.2756

Published: 2005

Journal Articles

Polymorphisms in Drug Metabolism/Disposition Genes and Increased Susceptibility to Adult De Novo AML: MDR1 and CYP3A4.

Meirav Kedmi, MD, Sara B. Cohen, PhD, Deborah Rund, MD

Blood (2004) 104 (11): 2078.

https://doi.org/10.1182/blood.V104.11.2078.2078

Published: 2004

NARROW

Progression of Follicular Lymphoma within 24 Months of First Treatment (POD -24) As a Predictor of Overall Survival - a Single Center Retrospective Analysis

Ibrutinib, Bendamustine, Rituximab Combination for Relapsed and Refractory Aggressive B Cell Lymphoma — Interim Analysis of Phase II Clinical Trial

Evaluation of the Risk of Hepatitis B Reactivation Among Patients with Chronic Myeloid Leukemia Treated with Tyrosine Kinase Inhibitors

Prognostic Value of Interim and End of Treatment FDG-PET/CT Scan Results in Adult Patients with Burkitt Lymphoma - a Retrospective Analysis of a Single Center Cohort

High Risk Advanced Stage Hodgkin Lymphoma Is Well Controlled with 2 Cycles of Escalated Beacopp Followed By 4 Cycles of ABVD in Patients Who Rapidly Achieve Metabolic CR on Interim PET/CT Scan

Low Proliferation Index May Be Associated with Longer Time to First Therapy In Low Grade Follicular Lymphoma

Drug Metabolism and Disposition Genes in Israeli HIV Patients: MDR1 and CYP3A4 Polymorphisms May Affect Susceptibility to HIV but Not the Course of the Disease.

MDR1 Polymorphisms but Not GST Null Phenotypes Alter Susceptibility to Acute Myeloid Leukemia in Young Adult Israeli Patients.

Polymorphisms in Drug Metabolism/Disposition Genes and Increased Susceptibility to Adult De Novo AML: MDR1 and CYP3A4.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only